JP2007537299A5 - - Google Patents

Download PDF

Info

Publication number
JP2007537299A5
JP2007537299A5 JP2007513459A JP2007513459A JP2007537299A5 JP 2007537299 A5 JP2007537299 A5 JP 2007537299A5 JP 2007513459 A JP2007513459 A JP 2007513459A JP 2007513459 A JP2007513459 A JP 2007513459A JP 2007537299 A5 JP2007537299 A5 JP 2007537299A5
Authority
JP
Japan
Prior art keywords
antibody
drug
medicament
medicament according
allograft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007537299A (ja
JP5161567B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/017048 external-priority patent/WO2005110481A2/en
Publication of JP2007537299A publication Critical patent/JP2007537299A/ja
Publication of JP2007537299A5 publication Critical patent/JP2007537299A5/ja
Application granted granted Critical
Publication of JP5161567B2 publication Critical patent/JP5161567B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007513459A 2004-05-14 2005-05-16 補体活性を阻害することによる同種移植片の生存の延長 Expired - Lifetime JP5161567B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14
US60/571,444 2004-05-14
PCT/US2005/017048 WO2005110481A2 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012246213A Division JP5590624B2 (ja) 2004-05-14 2012-11-08 補体活性を阻害することによる同種移植片の生存の延長

Publications (3)

Publication Number Publication Date
JP2007537299A JP2007537299A (ja) 2007-12-20
JP2007537299A5 true JP2007537299A5 (https=) 2008-07-03
JP5161567B2 JP5161567B2 (ja) 2013-03-13

Family

ID=35385551

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007513459A Expired - Lifetime JP5161567B2 (ja) 2004-05-14 2005-05-16 補体活性を阻害することによる同種移植片の生存の延長
JP2012246213A Expired - Lifetime JP5590624B2 (ja) 2004-05-14 2012-11-08 補体活性を阻害することによる同種移植片の生存の延長
JP2014021907A Withdrawn JP2014080438A (ja) 2004-05-14 2014-02-07 補体活性を阻害することによる同種移植片の生存の延長

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012246213A Expired - Lifetime JP5590624B2 (ja) 2004-05-14 2012-11-08 補体活性を阻害することによる同種移植片の生存の延長
JP2014021907A Withdrawn JP2014080438A (ja) 2004-05-14 2014-02-07 補体活性を阻害することによる同種移植片の生存の延長

Country Status (14)

Country Link
US (3) US20090028850A1 (https=)
EP (4) EP2338511A3 (https=)
JP (3) JP5161567B2 (https=)
AU (1) AU2005244012C1 (https=)
CA (1) CA2566716C (https=)
DK (1) DK1755674T3 (https=)
ES (1) ES2528362T3 (https=)
HK (2) HK1201758A1 (https=)
IL (2) IL179240A (https=)
NZ (1) NZ551308A (https=)
PL (1) PL1755674T3 (https=)
PT (1) PT1755674E (https=)
SI (1) SI1755674T1 (https=)
WO (1) WO2005110481A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
WO2011003098A1 (en) * 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
US20180311299A1 (en) * 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
EP4619020A1 (en) * 2022-12-08 2025-09-24 NovMetaPharma Co., Ltd. Composition and method for prolong survival of transplant and recipient

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
AU9149791A (en) * 1990-12-06 1992-07-08 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
AU748443B2 (en) * 1998-02-04 2002-06-06 General Hospital Corporation, The Costimulatory blockade and mixed chimerism in transplantation
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
WO2000027421A2 (en) 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
EP2896631A1 (en) * 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
BR0209319A (pt) * 2001-06-08 2004-07-20 Novartis Ag Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
ES2283594T5 (es) 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
AU2003209308A1 (en) 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
US7923010B2 (en) * 2003-09-11 2011-04-12 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP2338511A3 (en) 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
BRPI0511272A (pt) * 2004-05-17 2007-12-04 Combinatorx Inc métodos e reagentes para o tratamento de distúrbios imunoinflamatórios

Similar Documents

Publication Publication Date Title
JP2007537299A5 (https=)
JP2009528369A5 (https=)
KR101650264B1 (ko) 보체 활성을 저해함으로써 동종이식편의 생존 연장
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
de Fijter The impact of age on rejection in kidney transplantation
EP1567138B1 (en) Use of a diamide derivative for inhibiting chronic transplant rejection
Kann et al. Past, present, and future research in the field of composite tissue allotransplantation
Starzl The French heritage in clinical kidney transplantation
JP2002530354A5 (https=)
JP2006514015A5 (https=)
WO2019159731A1 (ja) 慢性移植肺機能不全の改善又は予防薬
US20240197816A1 (en) Composition and method for prolong survival of transplant and recipient
Dean et al. The immunosuppression of pigs: a review
Starzl et al. The enigma of graft acceptance
Siemionow et al. Perspectives for facial allograft transplantation in humans
Inoue et al. Cyclosporine and partial liver allotransplants in a simplified rat model
Siemionow et al. Clinical application of composite tissue allografts
Allografts Immunomodulation of the Composite Tissue Allograft
THOMSON et al. Influence of Cyclosporin A
Sharma et al. A Review on Pharmacology of Tacrolimus In Renal Transplant Patients
Hiotis Donor specific tolerance to rat hindlimb allografts with mixed cell chimerism
AU2011236106A1 (en) Prolongation of survival of an allograft by inhibiting complement activity